Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September

Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027

Adapting Clinical Development Strategies to an Evolving Landscape with Changing SOC

10:59 am - Wednesday 30th September 2026

Adapting Clinical Development Strategies to an Evolving Landscape with Changing SOC

Adapting Clinical Development Strategies to an Evolving Landscape with Changing SOC

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organized By